BioGaia ProTectis Drops
(different from ProDentis which is meant for oral health due to sub-type used within the Lactobacillus reuteri strain)
http://www.biogaia-prodentis.com/about-biogaia/
Latest Exp: 06/2019

Digestive Health Probiotic drops

BioGaia ProTectis drops is a dietary supplement containing Lactobacillus reuteri Protectis that has been tested in a number of clinical studies and proven both effective and safe for children.

Probiotics are dietary supplements, like vitamins and minerals.The word probiotic means ”for life” as opposed to antibiotic which means ”against life”. WHO defines probiotics as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Lactobacillus reuteri Protectis is BioGaia’s own patented probiotic bacteria. Because Lactobacillus reuteri Protectis naturally occurs in the human body it is uniquely adapted to reside in humans. With its exceptional and documented health benefits in several areas, Lactobacillus reuteri Protectis is considered a truly superior probiotic bacterium.

Recommended dose
5 drops daily. One dose consists of a minimum of 100 million live Lactobacillus reuteri Protectis. Shake well before use. Recommended daily dose should not be exceeded. This product should not be used as a substitute for a varied diet.

Ingredients
Sunflower oil, medium chain triglyceride oil and Lactobacillus reuteri dsm 17938 (Lactobacillus reuteri Protectis).

Results from a randomized, controlled pilot study in 76 infants with acute diarrhoea show that rapid diagnostic testing and Lactobacillus reuteri Protectis supplementation for 60 days was associated with a significant increase in 60-day adjusted standardized height and significantly less recurrent diarrhoea compared to standard care and placebo treatment. The study was conducted in Botswana and the preliminary results were presented at the Infectious Disease Week in San Diego, USA, on October 10 2015.

Diarrhoea kills and disables children
Diarrhoea is the second leading cause of mortality in the world among children under the age of five, as well as a major cause of both growth failure and delayed cognitive development. There is a clear need for improvements in diarrhoeal disease management in resource-limited settings.

The pilot study demonstrated that the use of rapid enteric diagnostics (permitting timely targeted antimicrobial therapy) and L. reuteri Protectis were both feasible in a resource-limited sub-Saharan African context. These interventions led to significant increases in growth and decreases in recurrent diarrhoea. The next step will be to validate these findings in a trial with a much larger number of children.

"In Botswana, as well as other sub-Saharan countries, long periods of diarrhoea not only causes death but also leads to stunting and cognitive impairments. The results from this pilot study are therefore very encouraging as they indicate that our L. reuteri Protectis could contribute, both in the short as well as in the long perspective, to a better quality of life in these exposed children”, says Peter Rothschild, President, BioGaia.

Latest press releases from BioGaia
2015-09-07 BioGaia to invest further in Infant Bacterial Therapeutics AB
2015-08-18 BioGaia AB Interim Report 1 January-30 June 2015
2015-07-30 BioGaia’s oral health probiotic reduces Candida in the elderly

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 12 October 2015, 12:00 pm CET.